Frazier Life Sciences Management, L.P.
Position in LXEO — Lexeo Therapeutics, Inc.
CIK 1892134
PALO ALTO, CA
Position in LXEO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$25,397,921
-$18,539,598 QoQ
Shares Held
4,424,725
0.0% QoQ
Ownership
5.64%
of shares outstanding
% of Portfolio
0.66%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LXEO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Frazier Life Sciences Management, L.P. holds $3,802,745,091 across 34 Biotechnology names. LXEO ranks #25 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
7,679,684 | $709,449,207 | |
| 2 | NAMS |
NewAmsterdam Pharma Co N.V.
|
16,943,774 | $542,370,205 | |
| 3 | ERAS |
Erasca, Inc.
|
24,675,188 | $399,244,541 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
3,448,139 | $256,058,802 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
9,874,511 | $232,643,479 | |
| 6 | MBX |
MBX Biosciences, Inc.
|
6,652,013 | $198,562,588 | |
| 7 | PHAT |
Phathom Pharmaceuticals, Inc.
|
12,466,489 | $138,502,692 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
4,567,274 | $136,333,128 |
All Filings in LXEO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $25,397,921 | 4,424,725 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $43,937,519 | 4,424,725 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $29,380,174 | 4,424,725 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $17,787,394 | 4,424,725 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,315,637 | 955,515 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $6,287,288 | 955,515 | Shares | Sole | 2025-02-18 | |
| 2024-09-30 | $11,307,105 | 1,250,786 | Shares | Sole | 2024-11-15 | |
| No filing history on record for this holder in this stock. | ||||||